The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 493-500

  Hernberg, Micaela M ^a   Hahka Kemppinen, Marjo H ^a   Pyrhönen, Seppo O ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Advanced melanoma; Helper cells; Peripheral blood; Suppressor cells; Survival

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CD4 ANTIGEN; CD8 ANTIGEN; DACARBAZINE; FINNFERON ALPHA; LOMUSTINE; OKT 4; OKT 8; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HELPER CELL; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SUPPRESSOR CELL; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DACARBAZINE; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; LOMUSTINE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VINBLASTINE;

EID: 13544265602     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00009     Document Type: Article

References (43)

1. Krown SE, Burk MW, Kirkwood JM, Kerr D, Morton DL, Oettgen HF. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep 1984; 68:723-726.
2. Mughal TI, Thomas MR, Robinson WA. Role of recombinant alpha-interferon in the treatment of advanced cutaneous malignant melanoma. Oncology 1991; 48:365-368.
3. Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology 1986; 172:275-282.
4. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11:1969-1977.
5. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759.
6. Falkson CI. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 1995; 12:35-40.
7. Pyrhonen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10:1919-1926.
8. Nathan FE, Berd D, Sato T, Shield JA, Shields CL, De Potter P, et al. BOLD+ interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 1997; 16:201-208.
9. Punt CJ, van Herpen CM, Jansen RL, Vreugdenhil G, Muller EW, de Mulder PH. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Br J Cancer 1997; 76:266-269.
10. Muhonen T, Hahka-Kemppinen M, Pakkala S, Pyrhonen S. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma. J Immunother 1994; 15:67-73.
11. Hernberg M, Muhonen T, Turunen JP, Hahka-Kemppinen M, Pyrhonen S. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol 1996; 14: 1690-1696.
12. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996; 74:670-676.
13. Hakansson A, Gustafsson B, Krysander L, Hakansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res 1998; 18:33-39.
14. Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer 2001; 85:1871-1877.
15. Hakansson A, Hakansson L, Gustafsson B, Krysander L, Rettrup B, Ruiter D, et al. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation. Melanoma Res 2003; 13:401-407.
16. Hermanek P, Sobin LH. Melanoma of skin. In: Hermanek P, Sobin LH (editors): TNM Classification of Malignant Tumours. Berlin, Heidelberg, New York, London, Paris: Springer-Verlag; 1987, pp. 89-91.
17. Knapp W. Leukocyte typing IV. In: Knapp W, et al. IVth International Workshop and Conference on Human Leukocyte Differentiation Antigens, Vienna, 1989. Vienna: Oxford University Press; 1989, pp. 747-780.
18. Jackson AL, Warner NL. Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL (editors): Manual of Clinical Immunology. Washington DC: American Society of Microbiology; 1986, pp. 226-235.
19. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989; 52:48-60.
20. Nicholson JK. Immunophenotyping specimens from HIV-infected persons: laboratory guidelines from the Centers for Disease Control and Prevention. Cytometry 1994; 18:55-59.
21. Hernberg M, Muhonen T, Pyrhonen S. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma? Ann Oncol 1997; 8:71-77.
22. Karavodin LM, Golub SH. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper: suppressor cell ratios in melanoma patients during interferon treatment. Nat Immun Cell Growth Regul 1983; 3:193-202.
23. Konjevic G, Jovic V, Radulovic S, Jelic S, Dzodic R, Spuzic I. Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha. Neoplasma 2001; 48:175-181.
24. Bernengo MG, Lisa F, Meregalli M, De Matteis A, Zina G. The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up. Cancer 1983; 52:1841-1848.
25. Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 1990; 50:5358-5364.
26. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res 1988; 48:1671-1675.
27. Bast RC Jr, Reinherz EL, Maver C, Lavin P, Schlossman SF. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 1983; 28: 101-114.
28. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343:1020-1034.
29. Royer HD, Reinherz EL. T lymphocytes: ontogeny, function, and relevance to clinical disorders. N Engl J Med 1987; 317:1136-1142.
30. Bernengo MG, Lisa F, Puiatti P, Meregalli M, Berruto G, Zina G. T-cell subsets in melanoma patients evaluated by anti-T-cell monoclonal antibodies. Thymus 1983; 5:223-233.
31. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-1310.
32. Hernberg M, Turunen JP, Muhonen T, Pyrhonen S. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 1997; 20:488-495.
33. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74:43-47.
34. Zehntner S, Townsend W, Parkes J, Schmidt C, Down M, Bell J, et al. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 1999; 31:116-122.
35. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996; 6:247-255.
36. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL. Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 2000; 6:1351-1364.
37. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors. Anticancer Res 2000; 20:1759-1768.
38. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189:753-756.
39. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19:720-726.
40. Li Y, McGowan P, Hellstrom I, Hellstrom KE, Chen L. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994; 153:421-428.
41. Wang XY, Kazim L, Repasky EA, Subjeck JR. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int J Cancer 2003; 105: 226-231.
42. Thomas WD, Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer 1998; 75:384-390.
43. Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 1997; 3(Suppl. 1):S9-S15.